MediaMedic

PROQURE-I: Promising Phase I Data on [¹⁷⁷Lu]Lu-PSMA-617 in Curative Treatment of N1 Prostate Cancer Presented by Dr. Lotte G. Zuur at EAU25

By Peng Longmei 2025.04.06

At #EAU25, Dr. Lotte Zuur from the The Netherlands Cancer Institute presented the first results of the PROQURE-I study, a phase I trial evaluating the addition of [¹⁷⁷Lu]Lu-PSMA-617 to standard…

“Shared decision-making isn’t just a concept—it’s a measurable determinant of patient satisfaction.”

By Peter W. PENG 2025.04.04

At hashtag#EAU25, André Deschamps presented the results of the Europa Uomo Patient REported Shared decision making Study (EU-PRESS), shedding light on the link between perceived shared decision-making (SDM) and decision…

Dr. Sarah Psutka MD MSc presents interim results from the SunRISe-4 trial at EAU25

By Mourabit Halima 2025.04.04

At the EAU25 Congress, Dr. Sarah Psutka MD MSc shared promising data from the SunRISe-4 trial evaluating neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer (MIBC) who are…

EAU25 | Dr. Dr. med. Yannic Volz Presents the PRACTICE Study: Can Prehabilitation Improve Radical Cystectomy Outcomes?

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Yannic Volz (Ludwig-Maximilians-Universität München) introduced early insights from the ongoing PRACTICE trial (NCT06806059), a randomized, single-blinded study assessing the impact of structured physical activity before radical cystectomy…

EAU25 | Sustainability in Uro-Oncology: Comparing the Carbon Footprint of RC vs CRT

By Peng Longmei 2025.04.03

At #EAU25, Dr. Vera R. and colleagues from Erasmus MC presented the first study to assess the environmental impact and staff requirements of radical cystectomy (RC) versus chemoradiation (CRT) for…

EAU25 | Dr. Seth Lerner Shares First-in-Human Results on Bel-sar (AU-011) in NMIBC

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Seth Lerner (Baylor College of Medicine) presented early findings from a Phase 1 study (NCT05483868) evaluating Bel-sar (AU-011)—a novel virus-like drug conjugate (VDC) for non-muscle invasive bladder…

EAU25 | Dr. Nikhil Mayor Presents NeuroSAFE PROOF Trial: Advancing Nerve-Sparing in Prostate Cancer Surgery

By Mourabit Halima 2025.04.01

At #EAU25, Dr.Nikhil Mayor (Imperial College London) presented results from the NeuroSAFE PROOF trial (NCT03317990)—the first randomized, controlled, single-blinded study comparing NeuroSAFE-guided versus standard robot-assisted radical prostatectomy (RARP) in localized…

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology

Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology

CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights

Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference

2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies

CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

PROQURE-I: Promising Phase I Data on [¹⁷⁷Lu]Lu-PSMA-617 in Curative Treatment of N1 Prostate Cancer Presented by Dr. Lotte G. Zuur at EAU25

“Shared decision-making isn’t just a concept—it’s a measurable determinant of patient satisfaction.”

Dr. Sarah Psutka MD MSc presents interim results from the SunRISe-4 trial at EAU25

EAU25 | Dr. Dr. med. Yannic Volz Presents the PRACTICE Study: Can Prehabilitation Improve Radical Cystectomy Outcomes?

EAU25 | Sustainability in Uro-Oncology: Comparing the Carbon Footprint of RC vs CRT

EAU25 | Dr. Seth Lerner Shares First-in-Human Results on Bel-sar (AU-011) in NMIBC

EAU25 | Dr. Nikhil Mayor Presents NeuroSAFE PROOF Trial: Advancing Nerve-Sparing in Prostate Cancer Surgery

EAU25 | NeuroSAFE PROOF Trial: Enhancing Functional Outcomes in Prostate Cancer Surgery

EAU25 | PERSIAN Trial: Can SBRT Enhance Systemic Therapy in Oligometastatic mHSPC?

EAU25 | PEACE-3 Trial Update: Bone-Protective Agents Improve Outcomes in mCRPC

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.